Roche
Roche’s Vabysmo approved by FDA for retinal vein occlusion treatment
October 27, 2023Medical Communications FDA, Opthalmology, Roche, Vabysmo, retinal vein occlusion
Roche has announced that the US Food and Drug Administration (FDA) has approved Vabysmo (farcimab) for the treatment of macular …
Roche announces acquisition of Telavant
October 23, 2023Business Services Gastrointestinal tract, Roche, Telavant
Roche has announced that it has entered into a definitive agreement to acquire Telavant Holdings, a Roivant company, owned by …
EC approves Roche’s Evrysdi for babies under two months with SMA
August 30, 2023Research and Development European Commission, Evrysdi, Musculo-skeletal disorder, Roche, spinal muscular atrophy
Roche has announced that the European Commission (EC) has approved the extension of Evrysdi’s marketing authorisation in the EU to …
Alnylam and Roche partner for RNAi therapeutic for treatment of hypertension
July 24, 2023Research and Development Alnylam, Cardiology, Roche, hypertension, rnai, zilebesiran
Alnylam Pharmaceuticals has announced that it has entered a strategic agreement with Roche for the development and commercialisation of zilebesiran, …
Nordic Bioscience receives FDA Letter of Support for biomarker in aggressive tumour fibrosis
June 16, 2023Research and Development FDA, Nordic Bioscience, Oncology, Roche, tumour fibrosis
Danish biomarker company Nordic Bioscience has announced that the US Food and Drug Administration (FDA) has awarded it a Letter …
Roche’s Evrysdi drug for SMA shown to significantly increase survival
April 15, 2021PTC Therapeutics, Roche, pharma, pharma news, spinal muscular atrophy
Roche’s Evrysdi therapy for the treatment of children with type 1 spinal muscular atrophy (SMA) has been shown to increase …
Novartis signs capacity and technology transfer agreement for Roche drug
April 15, 2021Novartis, Roche, production
Novartis has signed an initial agreement with Roche to reserve capacity and implement the technology transfer for the production of …
Roche’s SMA treatment Evrysdi approved by European Commission
March 30, 2021Manufacturing and Production EMA, European Commission, PTC Therapeutics, Roche, sma, spinal muscular atrophy
The European Commission has granted marketing authorisation to Roche and PTC Therapeutics’ Evrysdi, for the treatment of patients aged 2 …
Roche’s drug cocktail reduces hospitalisation due to COVID-19 in Phase III trial
March 24, 2021Research and Development COVID-19, Roche, covid-19 treatment
Roche’s antibody drug combination of casirivimab and imdevimab has shown to reduce hospitalisation or death by 70% in non-hospitalised patients …
Roche’s Huntington’s disease treatment disappoints in Phase III trial
March 23, 2021Manufacturing and Production Huntington's, Phase III trial, Roche, huntington's disease, tominersen
Roche has discontinued dosing in a Phase III trial of its tominersen treatment for Huntington’s disease, following discouraging initial data.
Roche lung cancer treatment reports promising results in Phase III
March 22, 2021Sales and Marketing Roche, oncology
Roche’s IMpower010 study, evaluating Tecentriq (atezolizumab) compared with best supportive care, has shown significant improvement in disease-free survival (DFS) in …
Roche and PTC’s SMA treatment shows positive trial results
March 16, 2021Manufacturing and Production PTC, PTC Therapeutics, Roche, sma, spinal muscular atrophy
Roche and PTC Therapeutics’s Evrysdi treatment for children and adults with Type 2 or Type 3 spinal muscular atrophy (SMA) …
Roche acquire GenMark in $1.8 billion deal
March 15, 2021Sales and Marketing Diagnostics, GenMark, Roche
Pharmaceutical giant Roche have bought GenMark Diagnostics in a deal worth $1.8 billion, expanding their infectious disease testing for illnesses …
Roche voluntarily withdraws Tecentriq’s US bladder cancer indication
March 8, 2021Sales and Marketing Cancer, Roche, bladder cancer, tecentriq
Roche has announced that the company is voluntarily withdrawing the US indication for Tecentriq (atezolizumab) in prior-platinum treated metastatic urothelial …
FDA approves Roche’s Actemra/RoActemra treatment for rare lung disease
March 5, 2021Medical Communications Actemra, RoActemra, Roche, SEC, systemic sclerosis
Roche’s Actemra/RoActemra therapy, intended for slowing the rate of decline in pulmonary function for adults with systemic sclerosis-associated interstitial lung …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
